CASI Pharmaceuticals (CASIF) Receivables - Other (2023 - 2024)

CASI Pharmaceuticals (CASIF) reported Receivables - Other of $209000.0 for Q1 2024, down 99.96% quarter-over-quarter from $587.0 million in Q4 2023.

CASI Pharmaceuticals (CASIF) Receivables - Other (2023 - 2024) Analysis & Trends

CASI Pharmaceuticals has reported Receivables - Other for 2 years, with the latest figure at $209000.0 in Q1 2024.

For the quarter ending Q1 2024, Receivables - Other changed N/A year-over-year to $209000.0; the trailing twelve-month figure through Mar 2024 stood at $209000.0 (changed N/A YoY), and the FY2023 full-year result was $587.0 million, changed N/A from the prior year.
Receivables - Other for Q1 2024 stood at $209000.0, down from $587.0 million in the prior quarter.
The five-year high for Receivables - Other was $587.0 million in Q4 2023, with the low at $209000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	860,679.92 Bn	860,679.89 Bn	-
2	Belite Bio	55,284.00 Bn	55,284.00 Bn	-
3	Quantum Biopharma	16,206.94 Bn	16,206.93 Bn	-
4	Legend Biotech	3,318.00 Bn	3,317.71 Bn	242.10 Mn
5	Akari Therapeutics	1,543.84 Bn	1,543.84 Bn	-
6	Evaxion A	1,449.11 Bn	1,449.09 Bn	-
7	Psyence Biomedical	216.99 Bn	216.98 Bn	-
8	Vertex Pharmaceuticals	115.22 Bn	107.97 Bn	2.59 Bn
9	Abivax	90.58 Bn	90.58 Bn	-
10	CASI Pharmaceuticals	-	-	3.69 Mn

Download Data